Trade secrets: an alternative for life sciences IP?

Over the past decade, three high-profile US Supreme Court decisions—known by their shorthand names as Alice, Mayo, and Myriad—have generated significant uncertainty over what is and isn’t patentable.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

10x Genomics wins latest round in Parse patent dispute

3 September 2026 Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.

MedTech

Sun Pharma import ban back in force after Squires intervention

3 September 2026 A decision at the USPTO has cleared the way for renewed enforcement in the drugmaker’s dispute over light-based dermatology tech.

Careers

White & Case life sciences co-leader moves firms

2 September 2026 The senior transactions specialist brings experience advising pharmaceutical, biotechnology and technology companies on strategic alliances, licensing, M&A and cross-border transactions.

More features

10x Genomics wins latest round in Parse patent dispute

The buyers' wishlist: What makes a life sciences deal stack up?

Former head of litigation at Nokia returns to Bird & Bird

Former USPTO acting director takes the helm at C4IP

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

Kirkland clears conflicts hurdle in trade secrets spat

The UPC plugs another gap in its procedural rulebook

Insulet asks Fed Circ to rehear $59.4m trade secret reversal

Trade secrets: an alternative for life sciences IP?

More on this story

Editor's picks

Editor's picks

More features